Why test an HIV vaccine here? Why now?
The University of Pennsylvania HIV Prevention Research Division is one of just 14 research facilities in the U.S. participating in a new study seeking a safe, effective, affordable HIV vaccine. We know HIV vaccines are our best hope of ending AIDS. Why here? Why now? And most importantly, why should you consider participating?
Over 19,835 Philadelphia AIDS cases (not HIV infections- just AIDS cases) have been reported to the city since the epidemic began in 1981. In 2006, estimates show that over 200 men who have sex with men were diagnosed with HIV infections in Philadelphia. Even though condoms and good HIV treatment medicines are available, men continue to become infected with HIV every day in Philadelphia.
Conducting an HIV vaccine trial is a significant undertaking that requires many resources and a thoughtful understanding of the affected community. UPenn’s HIV Prevention Research Division has longstanding expertise in this kind of project. The staff includes experienced doctors, nurses, and researchers as well as first-rate laboratory facilities. As important, the Penn group is highly committed to sustaining an excellent relationship with the GLBT community in Philadelphia.
Having the most committed research team, or even a potentially promising vaccine, are useless unless there are people willing to take the brave step of considering participation in vaccine research studies. Such an opportunity exists right now. UPenn is looking for 18 to 50 year old HIV negative men who have sex with men to participate in this HIV vaccine study. You cannot get HIV from the vaccine, but you can play a role in ending the HIV epidemic.
To learn more, call Penn at 1-866-448-7366, or go to http://hopetakesaction.org.
Follow UPenn’s HIV Vaccine Prevention Division on Twitter @PhillyVax